Roivant Sciences Ltd. (NASDAQ:ROIV) Stake Lessened by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank decreased its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 6.3% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 63,736 shares of the company’s stock after selling 4,283 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Roivant Sciences were worth $716,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ROIV. Handelsbanken Fonder AB grew its stake in Roivant Sciences by 22.3% during the 3rd quarter. Handelsbanken Fonder AB now owns 81,909 shares of the company’s stock valued at $957,000 after acquiring an additional 14,909 shares in the last quarter. Xponance Inc. grew its position in Roivant Sciences by 39.7% during the third quarter. Xponance Inc. now owns 46,804 shares of the company’s stock valued at $547,000 after purchasing an additional 13,291 shares in the last quarter. Maryland State Retirement & Pension System increased its stake in Roivant Sciences by 38.7% in the 3rd quarter. Maryland State Retirement & Pension System now owns 26,741 shares of the company’s stock valued at $312,000 after buying an additional 7,461 shares during the period. Bank of New York Mellon Corp lifted its position in Roivant Sciences by 68.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,187,928 shares of the company’s stock worth $13,875,000 after buying an additional 480,946 shares in the last quarter. Finally, Strs Ohio acquired a new stake in shares of Roivant Sciences during the 3rd quarter valued at $704,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Stock Up 0.9 %

Roivant Sciences stock opened at $11.13 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 27.79 and a quick ratio of 27.79. Roivant Sciences Ltd. has a fifty-two week low of $8.06 and a fifty-two week high of $13.24. The firm has a fifty day moving average price of $10.91 and a two-hundred day moving average price of $10.38. The firm has a market cap of $8.97 billion, a price-to-earnings ratio of 2.14 and a beta of 1.34.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Tuesday, February 13th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.07. The business had revenue of $37.14 million during the quarter, compared to analysts’ expectations of $30.72 million. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. As a group, analysts forecast that Roivant Sciences Ltd. will post -1.36 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. The Goldman Sachs Group upped their price target on shares of Roivant Sciences from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Piper Sandler initiated coverage on shares of Roivant Sciences in a research report on Friday, January 5th. They set an “overweight” rating and a $20.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Monday, April 22nd. Bank of America increased their price target on shares of Roivant Sciences from $11.00 to $12.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 2nd. Finally, Truist Financial reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Roivant Sciences in a research note on Monday, March 25th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.90.

Insider Transactions at Roivant Sciences

In other news, COO Eric Venker sold 96,950 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $10.92, for a total value of $1,058,694.00. Following the sale, the chief operating officer now owns 532,207 shares in the company, valued at $5,811,700.44. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 4.60% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.